This retrospective study evaluated the clinical efficacy of either a BRAFinhibitor (dabrafenib) alone or a BRAF inhibitor (dabrafenib) in combinationwith a MEK inhibitor (trametinib) in the treatment of 10 patients diagnosedwith metastatic BRAF-mutant RAI refractory thyroid cancer. The gene discussed is MAP2K7; the disease is thyroid gland carcinoma.